Subscribe To
TRML / Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6
Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease. The ongoing phase 2b spiriTED study, which is using TOUR006 for the treatment of patients with active TED, is expected to release results in the first half of 2025. A phase 2 study, using TOUR006 for the treatment of patients with atherosclerotic cardiovascular disease, is expected to begin in 2024.
Read More
Posted: Nov 1 2023, 14:09
Author Name: Seeking Alpha
Views: 112247
TRML News
By Seeking Alpha
November 1, 2023
Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6
Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease. more_horizontal